Jellinger Kurt A, Seppi Klaus, Wenning Gregor K
Institute of Clinical Neurobiology, Vienna, Austria.
Mov Disord. 2005 Aug;20 Suppl 12:S29-36. doi: 10.1002/mds.20537.
Multiple system atrophy (MSA), a sporadic progressive synucleinopathy of advanced age, is separated into two clinic opathological subtypes: MSA-P (striatonigral degeneration [SND]) with predominant parkinsonian features and MSA-C (olivopontocerebellar atrophy [OPCA]) with predominant cerebellar ataxia. We propose a novel morphological grading system for both subtypes to compare lesion intensities and their possible clinical validity. Forty-two autopsy cases of MSA were separated into four grades (SND 0-III and OPCA 0-III) based on semiquantitative assessment of neuronal loss, astrogliosis, and presence of alpha-synuclein-positive glial cytoplasmic inclusions (GCI) in striatum, globus pallidus, substantia nigra, pontine basis, cerebellum, and inferior olives. Whereas a recent grading system restricted to SND reflected disease progression and dopa-responsiveness, there was considerable variation in the morphological combination between SND and OPCA, with only around half the cases with OPCA II (moderate) and III (severe) showing comparable grades of both types, whereas OPCA 0 and I (no or little degeneration) was combined with all grades of SND. Twenty-two cases showing OPCA 0 + SND II (n = 3), OPCA I + SND I-II (n = 11), and OPCA I + SND III (n = 8) were classified as pure or predominant SND, consistent with MSA-P. Twenty cases showing OPCA II + SND II/III (n = 7) and OPCA III + SND III (n = 13) were classified as predominant OPCA, consistent with MSA-C. In MSA-P, the mean age of onset was higher than it was in MSA-C (55.1 vs. 50.5 years), but the mean duration of illness was shorter in MSA-P (5.3 vs. 6.7 years). Presenting symptoms in MSA-P were mainly parkinsonism, whereas in MSA-C they were mainly gait disorders (14 vs. 1; P < 0.001). Among clinical key symptoms, parkinsonism was more frequent than were cerebellar signs in MSA-P; in MSA-C it was the reverse (P < 0.01), whereas other symptoms (autonomic/urinary failure) showed no differences. Parkinsonism was infrequent in MSA-C even when OPCA was associated with SND, suggesting a masking effect by cerebellar system involvement. High terminal Hoehn and Yahr stages were more frequent in MSA-P (P < 0.01), some with good-to-moderate initial levodopa (L-dopa) response. Although the proposed morphological grading of both MSA-P and -C correlates well with initial symptoms and clinical key features of both types, further prospective studies are required to validate the clinical utility of the proposed MSA grading scales for future intervention studies.
多系统萎缩(MSA)是一种好发于老年人的散发性进行性突触核蛋白病,可分为两种临床病理亚型:以帕金森综合征为主要特征的MSA-P(纹状体黑质变性[SND])和以小脑性共济失调为主要特征的MSA-C(橄榄脑桥小脑萎缩[OPCA])。我们为这两种亚型提出了一种新的形态学分级系统,以比较病变强度及其可能的临床有效性。42例MSA尸检病例根据对纹状体、苍白球、黑质、脑桥基底部、小脑和下橄榄核中神经元丢失、星形胶质细胞增生以及α-突触核蛋白阳性胶质细胞质包涵体(GCI)的存在情况进行半定量评估,分为四个等级(SND 0 - III级和OPCA 0 - III级)。尽管最近一个仅限于SND的分级系统反映了疾病进展和对多巴的反应性,但SND和OPCA之间的形态学组合存在相当大的差异,只有约一半的OPCA II级(中度)和III级(重度)病例显示两种类型的分级相当,而OPCA 0级和I级(无或轻度退变)与所有等级的SND组合。22例表现为OPCA 0 + SND II(n = 3)、OPCA I + SND I-II(n = 11)和OPCA I + SND III(n = 8)的病例被归类为纯或主要为SND,符合MSA-P。20例表现为OPCA II + SND II/III(n = 7)和OPCA III + SND III(n = 13)的病例被归类为主要为OPCA,符合MSA-C。在MSA-P中,平均发病年龄高于MSA-C(55.1岁对50.5岁),但MSA-P的平均病程较短(5.3年对6.7年)。MSA-P的首发症状主要是帕金森综合征,而MSA-C的首发症状主要是步态障碍(14例对1例;P < 0.001)。在临床关键症状中,帕金森综合征在MSA-P中比小脑体征更常见;在MSA-C中则相反(P < 0.01),而其他症状(自主神经/泌尿功能衰竭)无差异。即使OPCA与SND相关,帕金森综合征在MSA-C中也不常见,提示小脑系统受累有掩盖作用。MSA-P中晚期Hoehn和Yahr分期更常见(P < 0.01),一些患者对左旋多巴(L-dopa)有良好至中度的初始反应。尽管所提出的MSA-P和-C的形态学分级与两种类型的初始症状和临床关键特征相关性良好,但需要进一步的前瞻性研究来验证所提出的MSA分级量表在未来干预研究中的临床实用性。